Cargando…

Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study( )

AIMS: There is currently no consensus on whether atrial fibrillation (AF) patients at low risk for stroke (one non-sex-related CHA(2)DS(2)-VASc point) should be treated with an oral anticoagulant. METHODS AND RESULTS: We conducted a multi-country cohort study in Sweden, Denmark, Norway, and Scotland...

Descripción completa

Detalles Bibliográficos
Autores principales:	Komen, Joris J, Pottegård, Anton, Mantel-Teeuwisse, Aukje K, Forslund, Tomas, Hjemdahl, Paul, Wettermark, Björn, Hallas, Jesper, Olesen, Morten, Bennie, Marion, Mueller, Tanja, Carragher, Raymond, Karlstad, Øystein, Kjerpeseth, Lars J, Klungel, Olaf H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547505/ https://www.ncbi.nlm.nih.gov/pubmed/35265981 http://dx.doi.org/10.1093/eurheartj/ehac111

Ejemplares similares

Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries
por: Komen, Joris J, et al.
Publicado: (2021)

Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds
por: Komen, Joris, et al.
Publicado: (2022)

Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk
por: Komen, Joris J, et al.
Publicado: (2020)

Response to: Kumar N, Ahmed M. Letter to the editor in response to Komen et al. 2021
por: Komen, Joris J, et al.
Publicado: (2021)

Association of preceding antithrombotic therapy in atrial fibrillation patients with ischaemic stroke, intracranial haemorrhage, or gastrointestinal bleed and mortality
por: Komen, Joris J, et al.
Publicado: (2019)

Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs
por: Komen, Joris, et al.
Publicado: (2017)

Usage, Risk, and Benefit of Weight-Loss Drugs in Primary Care
por: Forslund, Tomas, et al.
Publicado: (2011)

Who prescribes drugs to patients: A Danish register‐based study
por: Pottegård, Anton, et al.
Publicado: (2021)

Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
por: Kjerpeseth, Lars J., et al.
Publicado: (2019)

Impact of regulatory requirements on medicine registration in African countries – perceptions and experiences of pharmaceutical companies in South Africa
por: Narsai, Kirti, et al.
Publicado: (2012)

Greedy caliper propensity score matching can yield variable estimates of the treatment‐outcome association—A simulation study
por: Komen, Joris J., et al.
Publicado: (2021)

Pre‐approval and post‐approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs
por: Bloem, Lourens T., et al.
Publicado: (2022)

New use of prescription drugs prior to a cancer diagnosis
por: Pottegård, Anton, et al.
Publicado: (2016)

Occurrence and clinical management of moderate-to-severe adverse events during drug-resistant tuberculosis treatment: a retrospective cohort study
por: Sagwa, Evans L, et al.
Publicado: (2014)

Regulatory Scientific Advice on Non-Inferiority Drug Trials
por: Wangge, Grace, et al.
Publicado: (2013)

The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs
por: Vreman, Rick A., et al.
Publicado: (2020)

The Validity of Danish Prescription Data to Measure Use of Aspirin and Other Non-Steroidal Anti-Inflammatory Drugs and Quantification of Bias Due to Non-Prescription Drug Use
por: Gaster, Natascha, et al.
Publicado: (2021)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

Cox regression using a calendar time scale was unbiased in simulations of COVID-19 vaccine effectiveness & safety
por: Lund, Lars Christian, et al.
Publicado: (2023)

Effectiveness and safety of direct oral anticoagulants in atrial fibrillation patients switched from vitamin K antagonists: A systematic review and meta‐analysis
por: Hellfritzsch, Maja, et al.
Publicado: (2019)

Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation
por: Hellfritzsch, Maja, et al.
Publicado: (2017)

Availability, prices and affordability of UN Commission’s lifesaving medicines for reproductive and maternal health in Uganda
por: Kibira, Denis, et al.
Publicado: (2017)

A new likelihood model for analyses of pharmacoepidemiologic case–control studies which avoids decision rules for determining latent exposure status
por: Støvring, Henrik, et al.
Publicado: (2021)

Comparison of the Five Danish Regions Regarding Demographic Characteristics, Healthcare Utilization, and Medication Use—A Descriptive Cross-Sectional Study
por: Henriksen, Daniel Pilsgaard, et al.
Publicado: (2015)

Selection of Essential Medicines for Diabetes in Low and Middle Income Countries: A Survey of 32 National Essential Medicines Lists
por: Bazargani, Yaser T., et al.
Publicado: (2014)

Characteristics of drugs safety signals that predict safety related product information update
por: Insani, Widya N., et al.
Publicado: (2018)

The double opioid crisis: A call for balance
por: Vranken, Marjolein J.M., et al.
Publicado: (2019)

Systematic reviews of ten pharmaceutical pricing policies – a research protocol
por: Tordrup, David, et al.
Publicado: (2020)

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study
por: Pottegård, Anton, et al.
Publicado: (2021)

Price changes of antibiotics and perceived substitutes in the context of OTC policy changes in Mexico and Brazil
por: Santa-Ana-Tellez, Yared, et al.
Publicado: (2015)

Five-year trends in treatment changes in an adult cohort of HIV/AIDS patients in Ghana: a retrospective cohort study
por: Ankrah, Daniel N. A., et al.
Publicado: (2017)

Sustainable Development Goal indicator for measuring availability and affordability of medicines for children: a proof-of-concept study
por: Joosse, Iris R, et al.
Publicado: (2023)

When Reality Does Not Meet Expectations—Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs
por: Callenbach, Marcelien H. E., et al.
Publicado: (2022)

Prophylactic anticoagulation with low molecular weight heparin in COVID-19: cohort studies in Denmark and Sweden
por: Lund, Lars Christian, et al.
Publicado: (2022)

Valproic acid utilization among girls and women in Stockholm: Impact of regulatory restrictions
por: Karlsson Lind, Linnéa, et al.
Publicado: (2018)

Use of proton pump inhibitors after antireflux surgery: a nationwide register-based follow-up study
por: Lødrup, Anders, et al.
Publicado: (2014)

Description of a practice model for pharmacist medication review in a general practice setting
por: Brandt, Mette, et al.
Publicado: (2014)

Children's relative age in class and use of medication for ADHD: a Danish Nationwide Study
por: Pottegård, Anton, et al.
Publicado: (2014)

Essential Medicines Are More Available than Other Medicines around the Globe
por: Bazargani, Yaser T., et al.
Publicado: (2014)

Real World Data in Health Technology Assessment of Complex Health Technologies
por: Hogervorst, Milou A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dfubd4r5kr3rlbrjr7vtq512ug